- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Shilpa Medicare Limited — Important, 24-07-2025: General Updates
24-07-2025 | 06:57 pm
24-07-2025 | 06:57 pm
Shilpa Medicare's subsidiary is making a strategic US$ 2 million investment in US biotech startup Alveolus Bio through SAFE Notes. This positions Shilpa Biologics as the exclusive global development and manufacturing partner for Alveolus, which is advancing inhaled therapies for lung diseases. This move significantly strengthens Shilpa's global biologics footprint and CDMO capabilities. The investment will fund Alveolus Bio's lead COPD program through Phase 2 clinical trials, showcasing Shilpa's commitment to diversifying into innovative therapeutic platforms.
No comments yet. Be the first to comment!